Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety
Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety
复制标题
DOI：
10.3945/ajcn.112.047563
复制
发表时间：
2013-05-01
影响因子：
7.1
通讯作者：
Astrup, Arne
中科院分区：
文献类型：
--
作者：
Belza, Anita;Ritz, Christian;Astrup, Arne
背景：蛋白质摄入量对食欲调节激素及其动态的影响尚不清楚。目的：我们研究了不同蛋白质含量的膳食的饱腹感效果，以及剂量是否对食欲调节激素和食欲评级有影响。设计：25 名男性 [平均 +/- SD 年龄：30.0 +/- 8.7 岁；体重指数（BMI；单位为 kg/m(2)）：25.9 +/- 4.7] 参加了三向、随机、双盲交叉研究。测试餐是等热量的，其中 30% 的能量来自脂肪和蛋白质含量，但以碳水化合物为代价进行了调整。测试膳食包括正常蛋白质（NP；14% 的能量来自蛋白质）、中高蛋白质（MHP；25% 的能量来自蛋白质）和高蛋白质（HP，50% 的能量来自蛋白质）。在 4 小时内每 0.5 小时评估一次食欲评级和血液样本。餐后4小时随意享用午餐。 结果：蛋白质增加，剂量依赖性胰高血糖素样肽-1（GLP-1）、肽YY（PYY）3-36和胰高血糖素； MHP 的反应分别提高了 10%、7% 和 47%；和 HP 产生的反应分别比 NP 高 20%、14% 和 116%（P < 0.03）。与NP相比，HP使胰岛素和胆囊收缩素增加，胃饥饿素和葡萄糖依赖性促胰岛素多肽减少（P < 0.05）。相比之下，MHP 的饱腹感和饱满度呈剂量依赖性增加 7% 和 6%，HP 则分别增加 16% 和 19%。与 NP (P < 0.001)。饥饿感和预期消耗量呈剂量依赖性下降 15%。与 NP 相比，MHP 降低了 13%，HP 降低了 25% 和 26%（P < 0.0003）。除了 GLP-1 (P = 0.006) 对综合食欲评分的累加效应外，GLP-1 和 PYY 3-36 (P = 0.03) 还存在联合效应。随意能量摄入没有显示差异。 结论：蛋白质剂量依赖性地增加饱腹感以及GLP-1、PYY 3-36和胰高血糖素，其可能至少部分地负责蛋白质的饱腹感刺激作用。该试验在 ClinicalTrials.gov 上注册为 NCT01561235。美国临床营养杂志 201.3；97：980-9。
Background: Effects of protein intake on appetite-regulating hormones and their dynamics are unclear.Objectives: We investigated the satiating effects of meals with varying protein contents and whether there was an effect of dose on appetite-regulating hormones and appetite ratings.Design: Twenty-five men [mean +/- SD age: 30.0 +/- 8.7 y; body mass index (BMI; in kg/m(2)): 25.9 +/- 4.7] participated in the 3-way, randomized, double-blind crossover study. Test meals were isocaloric with 30% of energy from fat and protein content adjusted' at the expense of carbohydrate. Test meals were normal protein (NP; 14% of energy from protein), medium-high protein (MHP; 25% of energy from protein), and high protein (HP,. 50% of energy from protein). Appetite ratings and blood samples were assessed every 0.5 h for 4 h. An ad libitum lunch was served 4 h after the meal.Results: Protein increased dose-dependently glucagon-like peptide-1 (GLP-1), peptide YY (PYY) 3-36, and glucagon; MHP produced 10%, 7%, and 47% greater responses, respectively; and HP produced 20%, 14%, and 116% greater responses, respectively, than did NP (P < 0.03). Compared with NP, HP increased insulin and cholecystokinin and decreased ghrelin and glucose-dependent insulinotropic polypeptide (P < 0.05). Satiety and fullness dose-dependently increased by 7% and 6% for MHP and 16% and 19% for HP compared. with NP (P < 0.001). Hunger and prospective consumption dose-dependently decreased by 15% and. 13% for MHP and by 25% and 26% for HP compared with NP (P < 0.0003). There was a combined effect of GLP-1 and PYY 3-36 (P = 0.03) next to the additive effect of GLP-1 (P = 0.006) on the composite appetite score. No difference was shown in ad libitum energy intake.Conclusion: Protein dose-dependently increased satiety and GLP- I, PYY 3-36, and glucagon, which may, at least in part, be responsible for the satiety-stimulating effect of protein. This trial was registered at clinicaltrials.gov as NCT01561235. Am J Clin Nutr 201.3;97:980-9.